The Role of Neutral Endopeptidase in Dogs With Evolving Congestive Heart Failure
- 1 April 1995
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 91 (7) , 2036-2042
- https://doi.org/10.1161/01.cir.91.7.2036
Abstract
Background Recent studies suggest that neurohumoral mechanisms including decreased renal responses to increases in atrial natriuretic factor (ANF) play a central role in the progression from asymptomatic cardiac dysfunction to advanced congestive heart failure (CHF) with sodium retention, vasoconstriction, and reduced exercise tolerance. Recognizing that neutral endopeptidase 24.11 degrades ANF and may be enhanced in CHF, we hypothesized that chronic neutral endopeptidase inhibition (NEP-I) would potentiate renal responses to exogenous ANF and alter the temporal evolution of sodium retention in evolving CHF by potentiation of increased endogenous ANF. Methods and Results We studied 13 conscious dogs with evolving CHF produced by rapid ventricular pacing at 250 beats per minute. Six of these dogs received NEP-I with candoxatril, 10 mg/kg PO BID, throughout evolving CHF. Responses to exogenous ANF, 10 μg/kg IV bolus, were assessed at baseline and after 6 days of CHF. Daily metabolic studies during evolving CHF with chronic NEP-I showed increased sodium excretion and renal cGMP generation consistent with enhanced renal activity of endogenous ANF compared with untreated controls. In addition, renal natriuretic and cGMP responses to exogenous ANF were intact in CHF with chronic NEP-I in contrast to markedly attenuated renal responses to exogenous ANF in untreated CHF. Despite enhanced ANF responsiveness and improved sodium balance in evolving CHF, a moderate degree of sodium retention was observed during chronic NEP-I in evolving CHF. Conclusions Enzymatic degradation by neutral endopeptidase limits local renal responses to increases in endogenous and exogenous ANF in CHF independent of changes in systemic hemodynamics or augmented plasma concentrations of ANF. The moderate sodium retention observed during evolving CHF despite chronic NEP-I probably reflects the antinatriuretic effects of hemodynamic and humoral factors independent of ANF activity.Keywords
This publication has 25 references indexed in Scilit:
- Renal tubular responsiveness to atrial natriuretic peptide in sodium-retaining chronic caval dogs. A possible role for kinins and luminal actions of the peptide.Journal of Clinical Investigation, 1992
- Effectiveness of endopeptidase inhibition (Candoxatril) in congestive heart failureThe American Journal of Cardiology, 1992
- Neutral endopeptidase inhibition potentiates the renal actions of atrial natriuretic factorKidney International, 1990
- UK-69, 578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diureticBiochemical and Biophysical Research Communications, 1989
- EFFECTS OF UK 69 578: A NOVEL ATRIOPEPTIDASE INHIBITORPublished by Elsevier ,1989
- Thiorphan, an Inhibitor of Endopeptidase 24.11, Potentiates the Natriuretic Activity of Atrial Natriuretic PeptideJournal of Cardiovascular Pharmacology, 1989
- Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion.Journal of Clinical Investigation, 1986
- Atrial Natriuretic Peptide Elevation in Congestive Heart Failure in the HumanScience, 1986
- The Kidney in Heart FailureNew England Journal of Medicine, 1977
- The renin-angiotensin-aldosterone system in congestive failure in conscious dogs.Journal of Clinical Investigation, 1976